By Market Intelligence Team

The Akili Interactive Labs' digital therapeutic EndeavorRx™ improved attention in two-thirds of children diagnosed with attention-deficit/hyperactivity disorder (ADHD) who used the software for two months. Data across four clinical trials consistently demonstrate over one-third of children with ADHD no longer showed attention impairment on at least one measure of objective attention. Improvements in attention during treatment were associated with improvements in math and reading performance. EndeavorRx can be used alone or with stimulants. The outcomes are from the STARS-Adjunct trial, a multi-site open-label study designed to evaluate the impact of EndeavorRx™ on impairments in daily life in children with ADHD.…